Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
4 Assignments
0 Petitions
Accused Products
Abstract
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson'"'"'s Disease, related human neurodegenerative diseases, and psychosis.
-
Citations
86 Claims
- 1. A composition comprising a compound of Formula (I):
-
9. A method for treating a neurodegemative disease comprising:
-
identifying a patient suffering from a neurodegenerative disease; and
administering to the patient an effective amount of an inverse agonist selective for a serotonin receptor;
whereby the dopaminergic therapy associated dyskinesia is reduced. - View Dependent Claims (10, 11, 12, 13, 14, 15, 16)
-
-
17. A method for treating dyskinesia associated with dopaminergic therapy comprising:
-
identifying a patient suffering from dopaminergic therapy associated dyskinesia;
administering to the patient an effective amount of an inverse agonist selective for a serotonin receptor;
whereby the dopaminergic therapy associated dyskinesia is reduced. - View Dependent Claims (18, 19, 20, 21, 22, 23, 24)
-
-
25. A method for treating dystonia, myoclonus, or tremor associated with dopaminergic therapy comprising:
-
identifying a patient suffering from dopaminergic therapy associated dystonia, myoclonus, or tremor;
administering to the patient an effective amount of an inverse agonist selective for a serotonin receptor;
whereby the dopaminergic therapy associated dystonia, myoclonus, or tremor is reduced. - View Dependent Claims (26, 27, 28, 29, 30, 31)
-
-
32. A method for treating psychosis associated with dopaminergic therapy comprising:
-
identifying a patient suffering from dopaminergic therapy associated psychosis;
administering to the patient an effective amount of an inverse agonist selective for a serotonin receptor;
whereby symptoms of dopaminergic therapy associated psychosis is reduced. - View Dependent Claims (33, 34, 35, 36, 37, 38, 39)
-
-
40. A method for treating a neuropsyhiatric disease comprising:
-
identifying a patient suffering from a neuropsyhiatric disease; and
administering to the patient an effective amount of an inverse agonist selective for a serotonin receptor. - View Dependent Claims (41, 42, 43, 44, 45, 46, 47)
-
-
48. A compound having the structure of Formula (I):
- 49. A method of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an amount of the compound of formula (I) that is effective in inhibiting the activity of the monoamine receptor.
- 59. A method of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an amount of the compound of formula (I) that is effective in inhibiting the activation of the monoamine receptor.
- 70. A method of treating a disease condition associated with a monoamine receptor comprising administering to a subject in need of such treatment a therapeutically effective amount of the compound of formula (I).
-
81. A method of treating schizophrenia comprising administering to a subject in need of such treatment a therapeutically effective amount the compound of formula (I).
-
82. A method of treating migraine comprising administering to a subject in need of such treatment a therapeutically effective amount of the compound of formula (I).
-
83. A method of treating psychosis comprising administering to a subject in need of such treatment a therapeutically effective amount of the compound of formula (I).
-
84. A method for identifying a genetic polymorphism predisposing a subject to being responsive the compound of formula (I), comprising:
-
administering to a subject a therapeutically effective amount of said compound;
measuring the response of said subject to said compound, thereby identifying a responsive subject having an ameliorated disease condition associated with a monoamine receptor; and
identifying a genetic polymorphism in the responsive subject, wherein the genetic polymorphism predisposes a subject to being responsive to said compound. - View Dependent Claims (85)
-
-
86. A method for identifying a subject suitable for treatment with the compound of formula (I), comprising detecting the presence of a polymorphism in a subject wherein the polymorphism predisposes the subject to being responsive to the compound, and wherein the presence of the polymorphism indicates that the subject is suitable for treatment with the compound of formula (I).
Specification